Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688739'
s PB Ratio Range Over the Past 10 Years
Min: 0.85 Med: 1.26 Max: 6.79
Current: 0.89
During the past 13 years, Liaoning Chengda Biotechnology Co's highest PB Ratio was 6.79. The lowest was 0.85. And the median was 1.26.
SHSE:688739's PB Ratio is ranked better than 83.58% of 1230
companies
in the Biotechnology industry
Industry Median: 2.75
vs SHSE:688739: 0.89
During the past 12 months, Liaoning Chengda Biotechnology Co's average Book Value Per Share Growth Rate was -2.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -1.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 11.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 19.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Liaoning Chengda Biotechnology Co was 41.80% per year. The lowest was -1.00% per year. And the median was 13.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Liaoning Chengda Biotechnology Co PB Ratio Related Terms
Liaoning Chengda Biotechnology Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688739 vs VRTX, REGN, RVMD: PB Ratio Comparison
For the Biotechnology subindustry, Liaoning Chengda Biotechnology Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liaoning Chengda Biotechnology Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Liaoning Chengda Biotechnology Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Liaoning Chengda Biotechnology Co's PB Ratio falls into.
Liaoning Chengda Biotechnology Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Liaoning Chengda Biotechnology Co (SHSE:688739) has a PB Ratio of 0.89 as of Aug. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Liaoning Chengda Biotechnology Co and its competitors. This is 29% below median its historical median of 1.26. Over the past decade, Liaoning Chengda Biotechnology Co's PB Ratio has ranged from 0.85 to 6.79. According to the industry distribution chart, Liaoning Chengda Biotechnology Co ranks #202 out of 1230 companies in the Biotechnology industry, placing it in the top 16.4%.
Is Liaoning Chengda Biotechnology Co's PB Ratio too high?
Liaoning Chengda Biotechnology Co's current PB Ratio of 0.89 is 29% below median its 10-year median of 1.26. Over the past 10 years, this metric has ranged from a low of 0.85 to a high of 6.79. The Biotechnology industry median PB Ratio is 2.75. Liaoning Chengda Biotechnology Co's value of 0.89 is 67.6% below this industry median. Based on the distribution chart, Liaoning Chengda Biotechnology Co ranks #202 out of 1230 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Liaoning Chengda Biotechnology Co has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Liaoning Chengda Biotechnology Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Liaoning Chengda Biotechnology Co ranks #202 out of 1230 companies for PB Ratio. This places Liaoning Chengda Biotechnology Co in the top 16% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.75. Liaoning Chengda Biotechnology Co's value of 0.89 is 67.6% below this benchmark. Historically, Liaoning Chengda Biotechnology Co's own PB Ratio has ranged from 0.85 to 6.79 over the past decade. While the company's 10-year median is 1.26 vs. the industry median of 2.75, Liaoning Chengda Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.75, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liaoning Chengda Biotechnology Co's current PB Ratio of 0.89 is 67.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Liaoning Chengda Biotechnology Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liaoning Chengda Biotechnology Co's current PB Ratio is 0.89, which is 29% below median its own 10-year median of 1.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liaoning Chengda Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Liaoning Chengda Biotechnology Co (SHSE:688739) is currently considered Fairly Valued. The stock's GF Value™ is ¥22.01, compared to a current price of ¥20.07 — trading 8.8% below its estimated fair value. The current PB Ratio is 0.89, which is 29% below median its 10-year median of 1.26 and 67.6% below the Biotechnology industry median of 2.75. Liaoning Chengda Biotechnology Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Liaoning Chengda Biotechnology Co (SHSE:688739), the current PB Ratio is 0.89 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Liaoning Chengda Biotechnology Co (SHSE:688739) Overvalued in 2026?
Based on GuruFocus' analysis, Liaoning Chengda Biotechnology Co stock appears to be undervalued.
The current stock price of ¥20.07 is trading 8.8% below its estimated GF Value™ of ¥22.01.
GuruFocus considers Liaoning Chengda Biotechnology Co to be Fairly Valued.
Key valuation signals for SHSE:688739:
PB Ratio: 0.89 (29% below median its 10-year median of 1.26)
GF Value™: ¥22.01 vs. price of ¥20.07 (8.8% below fair value)
Industry Position: 67.6% below the Biotechnology median (#202 of 1230)
No single metric tells the full story. See the SHSE:688739 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688739 has been successfully added to your 
